References
- Tansarli GS, Karageorgopoulos DE, Kapaskelis A, et al. Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Rev Anti Infect Ther. 2013;11:321–331.
- Chen CH, Lin LC, Chang YJ, et al. Infection control programs and antibiotic control programs to limit transmission of multi-drug resistant Acinetobacter baumannii infections: evolution of old problems and new challenges for institutes. Int J Environ Res Public Health. 2015;12:8871–8882.
- Vila J, Pachón J. Therapeutic options for Acinetobacter baumannii infections: an update. Expert Opin Pharmacother. 2012;13:2319–2336.
- Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med. 2015;36:85–98.
- European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2013. Stockholm: ECDC; 2014. [ cited 2015 October 2]. Available from: http://ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=1205
- Denys GA, Callister SM, Dowzicky MJ. Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.). Ann Clin Microbiol Antimicrob. 2013;12:24.
- Fernández-Cuenca F, Tomás-Carmona M, Caballero-Moyano F, et al. In vitro activity of 18 antimicrobial agents against clinical isolates of Acinetobacter spp.: multicenter national study GEIH-REIPI-Ab 2010. Enferm Infecc Microbiol Clin. 2013;31:4–9.
- Yan JJ, Jung JS, Lee JE, et al. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med. 2004;10:161–167.
- Smani Y, Domínguez-Herrera J, Ibáñez-Martínez J, et al. Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59:3920–3924.
- Mechkarska M, Prajeep M, Radosavljevic GD, et al. An analog of the host-defense peptide hymenochirin-1B with potent broad-spectrum activity against multidrug-resistant bacteria and immunomodulatory properties. Peptides. 2013;50:153–159.
- Wang CQ, Yang CS, Yang Y, et al. An apolipoprotein E mimetic peptide with activities against multidrug-resistant bacteria and immunomodulatory effects. J Pept Sci. 2013;19:745–750.
- Zhao L, KuoLee R, Harris G, et al. c-di-GMP protects against intranasal Acinetobacter baumannii infection in mice by chemokine induction and enhanced neutrophil recruitment. Int Immunopharmacol. 2011;11:1378–1383.
- Lin L, Tan B, Pantapalangkoor P, et al. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio. 2012;3:e00312–12.
- De Leeuw EP. Efficacy of the small molecule inhibitor of Lipid II BAS00127538 against Acinetobacter baumannii. Drug Des Devel Ther. 2014;8:1061–1064.
- Cebrero-Cangueiro T, Iglesias-Guerra F, Sánchez-Céspedes J, et al. In vitro activity of a library of piperazine derivatives against clinical strains of panresistant Acinetobacter baumannii. 10th International Symposium on the Biology of Acinetobacter; 2015, 142.
- Bozkurt-Guzel C, Savage PB, Akcali A, et al. Potential synergy activity of the novel ceragenin, CSA-13, against carbapenem-resistant Acinetobacter baumannii strains isolated from bacteremia patients. Biomed Res Int. 2014;2014:710273.
- Parra-Millán R, Jiménez-Mejías ME, Sánchez-Encinales V, et al. Efficacy of lysophosphatidylcholine (LPS) in antimicrobial combined therapy in severe infection murine experimental model. 10th International Symposium on the Biology of Acinetobacter; 2015, 50.
- Cox G, Koteva K, Wright GD. An unusual class of anthracyclines potentiate Gram-positive antibiotics in intrinsically resistant Gram-negative bacteria. J Antimicrob Chemother. 2014;69:1844–1855.
- Chusri S, Villanueva I, Voravuthikunchai SP, et al. Enhancing antibiotic activity: a strategy to control Acinetobacter infections. J Antimicrob Chemother. 2009;64:1203–1211.
- Sahu M, Sanjith S, Bhalekar P, et al. War against extended spectrum Beta lactamase and metallobetalactamase producing pathogens- novel adjuvant antimicrobial agent cse1034- an extended hope. J Clin Diagn Res. 2014;8:DC20–3.